NeuroPace, Inc. (NASDAQ:NPCE) Insider Sells $1,074,742.48 in Stock

NeuroPace, Inc. (NASDAQ:NPCE) insider Martha Morrell sold 78,334 shares of the company’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $13.72, for a total transaction of $1,074,742.48. Following the completion of the transaction, the insider now owns 81,993 shares in the company, valued at $1,124,943.96. This represents a 48.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Martha Morrell also recently made the following trade(s):

• On Wednesday, January 29th, Martha Morrell sold 100 shares of NeuroPace stock. The shares were sold at an average price of $15.00, for a total value of $1,500.00.
• On Friday, January 24th, Martha Morrell sold 3,200 shares of NeuroPace stock. The stock was sold at an average price of $15.01, for a total value of $48,032.00.

NeuroPace Trading Down 6.8 %

NPCE opened at $12.56 on Friday. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The firm has a market cap of $374.89 million, a price-to-earnings ratio of -12.56 and a beta of 2.05. NeuroPace, Inc. has a 12 month low of $5.45 and a 12 month high of $17.10. The stock has a fifty day moving average price of $12.66 and a 200-day moving average price of $9.60.

Wall Street Analyst Weigh In

NPCE has been the topic of a number of recent research reports. UBS Group assumed coverage on NeuroPace in a research report on Tuesday, January 21st. They set a “buy” rating and a $17.00 price target on the stock. Wells Fargo & Company increased their target price on shares of NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Thursday, January 30th. Finally, JPMorgan Chase & Co. raised their target price on shares of NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.80.

Hedge Funds Weigh In On NeuroPace

A number of large investors have recently added to or reduced their stakes in NPCE. Wells Fargo & Company MN boosted its holdings in shares of NeuroPace by 54.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,483 shares of the company’s stock valued at $73,000 after buying an additional 2,279 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in NeuroPace during the fourth quarter valued at approximately $29,000. Financial Advocates Investment Management boosted its stake in NeuroPace by 20.0% in the third quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock valued at $125,000 after acquiring an additional 3,000 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in NeuroPace by 21.2% in the fourth quarter. Bank of New York Mellon Corp now owns 29,342 shares of the company’s stock worth $328,000 after purchasing an additional 5,133 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of NeuroPace by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 322,973 shares of the company’s stock worth $3,615,000 after purchasing an additional 5,781 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.